Veracyte Q4 2021 revenue $67.3M (+95% YoY); guides 2022 revenue $260-275M

VERACYTE, INC.

2021-FY EPS reported -$1.11 revenue$219,514,000

Q4 2021 revenue $67.3M (+95% YoY); full-year 2021 revenue $219.5M (+87% YoY).
Net loss $10.5M in Q4 ($0.15 per share); full-year loss $75.6M ($1.11 per share).
Test volume grew to 22,300 in Q4 (+70% YoY); full-year volume 78,565 (+77% YoY).
2022 revenue guidance $260M-$275M, representing 18-25% YoY growth.
Completed acquisitions of Decipher Biosciences and HalioDx; launched Decipher Bladder test.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.